Royalty Pharma buys royalty rights on biopharmaceutical medicines and receives payments tied to those drugs' sales. RPRX reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 7 | Morgan Stanley | Maintained | Buy | |
| Sep 8 | TD Cowen | Maintained | Buy | |
| Aug 7 | JP Morgan | Maintained | Buy | |
| Jul 13 | TD Cowen | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in RPRX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RPRX is in one of them and how their past RPRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RPRX in an article yet. Here's the latest on the wider market.
RPRX Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Christopher LandauExecutive branch | Sell | $100K – $250K | Apr 28, 2025 | Jul 16, 2025 | 79 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Nov 14, 2024 | Dec 5, 2024 | 21 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Royalty Pharma
Royalty Pharma buys royalty rights on biopharmaceutical medicines, so it receives payments based on the sales of those drugs. It is based in New York. Its portfolio covers more than 35 marketed therapies across areas such as rare diseases, neuroscience, oncology, immunology and diabetes, along with some development-stage product candidates. Its customers are drug developers, from small and midsize biotechnology companies and academic or research institutions to large global pharmaceutical companies that sell the medicines.
- Headquarters
- New York, NY